Evidence map›Paper›PMID 42050257›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

The Dementias Platform UK PET/MR harmonisation and test-retest study: assessment of PET repeatability and reproducibility across the national network.

Pawel J Markiewicz, Gerard Thompson, Joanna M Wardlaw, Catriona Wimberley, Craig Ritchie, John-Paul Taylor, David Brooks, Ross Maxwell, Michael Firbank, Nigel Hoggard and 25 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Pawel J MarkiewiczSchool of Computer Science and Digital Technologies, London South Bank University, London, UK. pawel.markiewicz@lsbu.ac.uk.ORCID 0000-0002-3114-0773
Gerard ThompsonInstitute for Neuroscience and Cardiovascular Research, UK Dementia Research Institute, Edinburgh Imaging, University of Edinburgh, Edinburgh, UK.
Joanna M WardlawInstitute for Neuroscience and Cardiovascular Research, UK Dementia Research Institute, Edinburgh Imaging, University of Edinburgh, Edinburgh, UK.
Catriona WimberleySchool of Physics and Astronomy, University of Edinburgh, Edinburgh, UK.
Craig RitchieScottish Brain Sciences, Edinburgh, UK.
John-Paul TaylorTranslational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK.
David BrooksTranslational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK.
Ross MaxwellTranslational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK.
Michael FirbankTranslational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK.
Nigel HoggardSchool of Medicine and Population Health, Sheffield Institute of Translational Neuroscience, University of Sheffield, Sheffield, UK.
Li SuSchool of Medicine and Population Health, Sheffield Institute of Translational Neuroscience, University of Sheffield, Sheffield, UK.
Jim WildSchool of Medicine and Population Health, Sheffield Institute of Translational Neuroscience, University of Sheffield, Sheffield, UK.
Philip HillelSheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Victoria Rhodes-BradfordDivision of Neuroscience, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Laura M ParkesSchool of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
John T O'BrienDepartment of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, UK.
Stephen F CarterDepartment of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, UK.
Franklin I AigbirhioDepartment of Clinical Neurosciences, University of Cambridge School of Clinical Medicine, Cambridge, UK.
Tim FryerDepartment of Clinical Neurosciences, University of Cambridge School of Clinical Medicine, Cambridge, UK.
Paul M MatthewsDepartment of Brain Sciences, Imperial College London, London, UK.
Paresh MalhotraDepartment of Brain Sciences, Imperial College London, London, UK.
Gabrielle GreyDepartment of Brain Sciences, Imperial College London, London, UK.
Will HallettPerceptive Inc., London, UK.
Dilek OcalDementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, London, UK.
John C DicksonInstitute of Nuclear Medicine, University College London Hospital, London, UK.
Enrico De VitaDevelopmental Imaging and Biophysics Unit, Department of Developmental Neuroscience, University College London Great Ormond Street Institute of Child Health, London, UK.
David L ThomasDepartment of Translational Neuroscience and Stroke, UCL Queen Square Institute of Neurology, University College London, London, UK.
Nick C FoxDementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, London, UK.
Giorgios KrokosKing's College London & Guy's and St Thomas' PET Centre, Research Departments of Biomedical Computing and Early Life Imaging, King's College London, London, UK.
Jane E MackewnKing's College London & Guy's and St Thomas' PET Centre, Research Departments of Biomedical Computing and Early Life Imaging, King's College London, London, UK.
Paul MarsdenSchool of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.
Alexander HammersKing's College London & Guy's and St Thomas' PET Centre, Research Departments of Biomedical Computing and Early Life Imaging, King's College London, London, UK.
Karl Herholz *NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK.
Frederik Barkhof *Medical Physics and Biomedical Engineering, Hawkes Institute, University College London, London, UK.
Julian C Matthews *School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.

Funding

Alzheimer's Research UK ARUK-SRF2017B-1Horizon 2020 Framework Programme 115952Horizon 2020 Framework Programme MR/M024717Medical Research Council MR/N025792/1
6 · The paper itself

Abstract

purposePositron emission tomography combined with magnetic resonance imaging (PET/MR) has not yet achieved the level of adoption of PET/CT. This study aimed to harmonise PET imaging protocols across a national PET/MR network and to quantitatively assess whether PET/MR can achieve reliability comparable to PET/CT. While previous PET test-retest studies have demonstrated good repeatability, they have typically been limited to small cohorts or restricted site configurations.

methodsWe conducted a multi-site harmonisation and rigorous test-retest study across the network of eight PET/MR scanners. Thirty-seven healthy older participants (65-90 years) underwent harmonised one-hour amyloid PET/MR scans using either [[Formula: see text]F]flutemetamol or [[Formula: see text]F]florbetaben on two occasions. Retest scans were performed under conditions of same-site repeatability or multi-site reproducibility. Harmonised acquisition and reconstruction protocols were applied, and amyloid burden was quantified on the Centiloid (CL) scale.

resultsCL values across 74 scans showed excellent test-retest agreement (ICC = 0.968), improving to 0.987 after exclusion of one attenuation correction related outlier. Mean test-retest variability was 2.58%. No statistically significant differences were observed across repeatability versus reproducibility conditions, scanner types, or tracers. CL measurements were highly consistent with three independent blinded visual reads.

conclusionThis study demonstrates that harmonised PET/MR achieves high reliability comparable to PET/CT. Although the accuracy of attenuation maps requires checks, this study supports the use of PET/MR for quantitative amyloid imaging in research and therapeutic trials, and provides a valuable open resource of image and raw PET/MR data for further methodological development.

Indexed as

DementiaMagnetic Resonance ImagingMultimodal ImagingPositron-Emission TomographyAgedAged, 80 and overFemaleHumansMaleReproducibility of ResultsUnited KingdomAmyloidHarmonisationMulti-sitePETPET/MRRepeatabilityReproducibilityTest-Retest

Identifiers

PMID42050257
PMCPMC13249770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.